Avibactam

Evidence Level: L5 Predicted Indications: 50

Quick Overview

Item Value
Drug Name Avibactam
DrugBank ID DB09060
Brand Names (EU) Avibactam
Evidence Level L5
Predicted Indications 50
Top Prediction Score 99.98%

Approved Indication (EMA)

Emblaveo is indicated for the treatment of the following infections in adult patients (see sections 4.4 and 5.1):• Complicated intra-abdominal infection (cIAI)• Hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP) • Complicated urinary tract infection (cUTI), including pyelonephritisEmblaveo is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adult patients with limited treatment options (see sections 4.2, 4.4, and 5.1).C

Predicted New Indications

TxGNN model predictions for potential drug repurposing:

Rank Indication Score Source
1 pyelonephritis 99.98% DL
2 streptococcal pneumonia 99.70% DL
3 influenza, severe, susceptibility to 99.28% DL
4 ureter tuberculosis 99.11% DL
5 urinary schistosomiasis 99.06% DL
6 polyclonal hyperviscosity syndrome 99.01% DL
7 hyperamylasemia 99.01% DL
8 staphylococcus aureus infection 98.97% DL
9 renal tuberculosis 98.93% DL
10 squamous cell lung carcinoma 98.86% DL
11 congenital analbuminemia 98.84% DL
12 influenza 98.75% DL
13 blood group incompatibility 98.70% DL
14 mitochondrial oxidative phosphorylation disorder due to nuclear DNA anomalies 98.68% DL
15 premalignant hematological system disease 98.61% DL
16 monoclonal gammopathy 98.58% DL
17 cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency 98.43% DL
18 hematological disease associated with an acquired peripheral neuropathy 98.39% DL
19 congenital hematological disorder 98.34% DL
20 hematopoietic and lymphoid system neoplasm 98.32% DL

Showing top 20 of 50 predictions.

About TxGNN Predictions

Prediction Sources

Source Description
KG Knowledge Graph - Network topology-based associations
DL Deep Learning - Neural network score prediction

Evidence Levels

Level Definition
L1 Multiple Phase 3 RCTs / Systematic Reviews
L2 Single RCT or multiple Phase 2 trials
L3 Observational studies / Large case series
L4 Preclinical / Mechanistic / Case reports
L5 AI prediction only (current)

Clinical Validation Needed

Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.

Next Steps for Validation

  1. Literature Review: Search PubMed for existing evidence
  2. Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
  3. Mechanistic Analysis: Evaluate biological plausibility
  4. Preclinical Studies: Conduct in vitro/in vivo validation
  5. Clinical Trials: Design and conduct human studies

Data Access

Citation

If using this data, please cite:

@article{huang2023txgnn,
  title={A foundation model for clinician-centered drug repurposing},
  author={Huang, Kexin and others},
  journal={Nature Medicine},
  year={2023},
  doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.

Copyright © 2026 EuTxGNN Project. For research purposes only. Not medical advice.